https://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rssBioCentury feeden-USCopyright 2026 BioCentury, Inc.RSS Generatorhttps://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/z8oGLhcsSyi6zlYTKFwihttps://www.biocentury.com/articles?utm_source=bc_rss&utm_medium=rsshttps://www.biocentury.com/article/660090/with-first-clinical-data-due-next-year-scribe-to-test-ipo-market-finance-reporthttps://www.biocentury.com/article/660090/with-first-clinical-data-due-next-year-scribe-to-test-ipo-market-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEWITH FIRST CLINICAL DATA DUE NEXT YEAR, SCRIBE TO TEST IPO MARKET: FINANCE REPORTPlus: Kelun’s follow-on in Hong Kong; venture rounds for Alchemab, Pyrotech, Cyllene, BriStar and ForeFri, 10 Jul 2026 17:27:36 -0700https://www.biocentury.com/article/660099/fda-resumes-crl-releases-citing-commitment-to-transparencyhttps://www.biocentury.com/article/660099/fda-resumes-crl-releases-citing-commitment-to-transparency?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA RESUMES CRL RELEASES, CITING ‘COMMITMENT TO TRANSPARENCY’ New batch of complete response letters includes camrelizumab plus rivoceranib combo from Hengrui and ElevarFri, 10 Jul 2026 17:18:46 -0700https://www.biocentury.com/article/660088/perspective-sirnas-are-better-than-asoshttps://www.biocentury.com/article/660088/perspective-sirnas-are-better-than-asos?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EDITOR'S COMMENTARYPERSPECTIVE — SIRNAS ARE BETTER THAN ASOSWhy it might be time to just admit that siRNAs are the better modalityFri, 10 Jul 2026 16:08:19 -0700https://www.biocentury.com/article/660092/2q26-wrap-income-inequalityhttps://www.biocentury.com/article/660092/2q26-wrap-income-inequality?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCE2Q26 WRAP: INCOME INEQUALITYWinners, losers in biotech stock tiers in 2Q26Fri, 10 Jul 2026 15:50:30 -0700https://www.biocentury.com/article/660013/can-m-a-momentum-carry-biotech-through-year-endhttps://www.biocentury.com/article/660013/can-m-a-momentum-carry-biotech-through-year-end?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCECAN M&A MOMENTUM CARRY BIOTECH THROUGH YEAR-END?M&A enthusiasm is carrying biotech amid tepid reception for launches. What happens if the AI trade goes bust?Fri, 10 Jul 2026 15:06:17 -0700https://www.biocentury.com/article/660059/roivant-s-gline-from-spin-cos-to-commercial-convictionhttps://www.biocentury.com/article/660059/roivant-s-gline-from-spin-cos-to-commercial-conviction?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTROIVANT’S GLINE: FROM SPIN-COS TO COMMERCIAL CONVICTIONCEO Matt Gline on upcoming launch, portfolio construction, and AI in biotech R&DThu, 09 Jul 2026 18:15:18 -0700https://www.biocentury.com/article/660076/new-ceo-appointments-include-idorsia-arrakis-leadershttps://www.biocentury.com/article/660076/new-ceo-appointments-include-idorsia-arrakis-leaders?utm_source=bc_rss&utm_medium=rssBIOCENTURY | MANAGEMENT TRACKSNEW CEO APPOINTMENTS INCLUDE IDORSIA, ARRAKIS LEADERSPlus: New hires at Jeito, Stipple, Vera and moreThu, 09 Jul 2026 17:30:30 -0700https://www.biocentury.com/article/660071/science-spotlight-actionable-pathways-for-cachexia-and-radioresistance-in-lung-cancerhttps://www.biocentury.com/article/660071/science-spotlight-actionable-pathways-for-cachexia-and-radioresistance-in-lung-cancer?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: ACTIONABLE PATHWAYS FOR CACHEXIA AND RADIORESISTANCE IN LUNG CANCERBioCentury’s translational roundup also includes a muscle-specific PROTAC platform and a dual tumor and TME-targeting CAR T therapy for glioblastomaThu, 09 Jul 2026 17:11:42 -0700https://www.biocentury.com/article/660068/ionis-attr-cm-miss-were-overlapping-mechanisms-or-the-modality-to-blamehttps://www.biocentury.com/article/660068/ionis-attr-cm-miss-were-overlapping-mechanisms-or-the-modality-to-blame?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTIONIS’ ATTR-CM MISS: WERE OVERLAPPING MECHANISMS OR THE MODALITY TO BLAME?Eplontersen from Ionis, AZ misses in Phase III ATTR-CM studyThu, 09 Jul 2026 16:54:48 -0700https://www.biocentury.com/article/660055/biotech-in-burnham-s-britainhttps://www.biocentury.com/article/660055/biotech-in-burnham-s-britain?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWBIOTECH IN BURNHAM’S BRITAINWhat does the incoming prime minister’s agenda mean for U.K. life sciences?Thu, 09 Jul 2026 13:43:15 -0700https://www.biocentury.com/article/659795/parcelbio-engineering-potent-and-durable-mrna-for-in-vivo-car-tshttps://www.biocentury.com/article/659795/parcelbio-engineering-potent-and-durable-mrna-for-in-vivo-car-ts?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEPARCELBIO: ENGINEERING POTENT AND DURABLE MRNA FOR IN VIVO CAR TSParcelBio’s APEXm mRNA platform aims for deeper immune reset over both linear and circular RNA designsWed, 08 Jul 2026 18:03:28 -0700https://www.biocentury.com/article/659977/race-to-cure-hbv-moves-to-targeting-the-reservoirhttps://www.biocentury.com/article/659977/race-to-cure-hbv-moves-to-targeting-the-reservoir?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTRACE TO CURE HBV MOVES TO TARGETING THE RESERVOIRPrecision cuts HBV cccDNA while Tune and nChroma aim to shut it down with CRISPR‑based epigenetic silencersWed, 08 Jul 2026 18:01:18 -0700https://www.biocentury.com/article/660060/fda-to-shore-up-legal-basis-for-crl-disclosures-as-it-pauses-new-releaseshttps://www.biocentury.com/article/660060/fda-to-shore-up-legal-basis-for-crl-disclosures-as-it-pauses-new-releases?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONFDA TO SHORE UP LEGAL BASIS FOR CRL DISCLOSURES AS IT PAUSES NEW RELEASESProposed legal framework for disclosing complete response letters for unapproved drugs to be released in OctoberWed, 08 Jul 2026 16:45:59 -0700https://www.biocentury.com/article/660026/big-week-for-m-a-brings-three-rare-disease-takeouts-deals-reporthttps://www.biocentury.com/article/660026/big-week-for-m-a-brings-three-rare-disease-takeouts-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSBIG WEEK FOR M&A BRINGS THREE RARE DISEASE TAKEOUTS: DEALS REPORTFour takeouts add up to almost $13B Tue, 07 Jul 2026 17:39:04 -0700https://www.biocentury.com/article/659997/takeda-s-orexin-program-the-hits-the-misses-and-the-payoffhttps://www.biocentury.com/article/659997/takeda-s-orexin-program-the-hits-the-misses-and-the-payoff?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTTAKEDA’S OREXIN PROGRAM: THE HITS, THE MISSES AND THE PAYOFFResearchers from the Japanese pharma on how they executed the oveporexton program for narcolepsyTue, 07 Jul 2026 17:13:18 -0700https://www.biocentury.com/article/660045/makary-era-reversals-continue-with-another-ultra-rare-u-turn-by-fdahttps://www.biocentury.com/article/660045/makary-era-reversals-continue-with-another-ultra-rare-u-turn-by-fda?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONMAKARY ERA REVERSALS CONTINUE WITH ANOTHER ULTRA-RARE U-TURN BY FDAAgency clears Saol to resubmit ultra-rare disease NDA, dropping demand for a new trialTue, 07 Jul 2026 17:07:25 -0700https://www.biocentury.com/article/660040/vertex-further-diversifies-with-fifth-pillar-via-10b-crinetics-acquisitionhttps://www.biocentury.com/article/660040/vertex-further-diversifies-with-fifth-pillar-via-10b-crinetics-acquisition?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSVERTEX FURTHER DIVERSIFIES WITH ‘FIFTH PILLAR’ VIA $10B CRINETICS ACQUISITIONStill heavily reliant on cystic fibrosis drugs, Vertex sees $5B peak potential in pair of assets for rare endocrinology indicationsTue, 07 Jul 2026 13:25:08 -0700https://www.biocentury.com/article/660030/chrna7-viability-uncertain-after-neuphoria-s-phase-ii-alzheimer-s-misshttps://www.biocentury.com/article/660030/chrna7-viability-uncertain-after-neuphoria-s-phase-ii-alzheimer-s-miss?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTCHRNA7 VIABILITY UNCERTAIN AFTER NEUPHORIA’S PHASE II ALZHEIMER’S MISSBioCentury’s Clinical Report, July 1–6Mon, 06 Jul 2026 16:48:02 -0700https://www.biocentury.com/article/660028/with-1-1b-myricx-buy-novartis-takes-plunge-into-adcshttps://www.biocentury.com/article/660028/with-1-1b-myricx-buy-novartis-takes-plunge-into-adcs?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSWITH $1.1B MYRICX BUY, NOVARTIS TAKES PLUNGE INTO ADCSSwiss pharma acquires preclinical U.K. company with novel payloads, rewarding syndicate of early-stage VCsMon, 06 Jul 2026 16:33:14 -0700https://www.biocentury.com/article/660033/novartis-adc-gambit-regulation-as-catalyst-for-u-k-biotech-a-biocentury-podcasthttps://www.biocentury.com/article/660033/novartis-adc-gambit-regulation-as-catalyst-for-u-k-biotech-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSNOVARTIS’ ADC GAMBIT & REGULATION AS CATALYST FOR U.K. BIOTECH — A BIOCENTURY PODCASTPlus: Lawmaker’s loss blow to FDA reforms, Parkinson’s insights, and the latest China probeMon, 06 Jul 2026 16:16:07 -0700https://www.biocentury.com/article/660018/puretech-backed-celea-preps-ipf-study-with-fresh-180m-round-finance-reporthttps://www.biocentury.com/article/660018/puretech-backed-celea-preps-ipf-study-with-fresh-180m-round-finance-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEPURETECH-BACKED CELEA PREPS IPF STUDY WITH FRESH $180M ROUND: FINANCE REPORTPlus: Abivax’s upsized follow-on, BridgeBio draws cash to support launches, and moreThu, 02 Jul 2026 11:25:07 -0700https://www.biocentury.com/article/659881/atlas-insights-targetable-directions-in-parkinson-s-diseasehttps://www.biocentury.com/article/659881/atlas-insights-targetable-directions-in-parkinson-s-disease?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONATLAS INSIGHTS: TARGETABLE DIRECTIONS IN PARKINSON’S DISEASESingle-cell Parkinson’s atlases reveal neuronal and glial disruptions in specific regions and stagesThu, 02 Jul 2026 11:15:36 -0700https://www.biocentury.com/article/659996/science-spotlight-tumor-lactate-as-a-druggable-node-in-cancer-immunityhttps://www.biocentury.com/article/659996/science-spotlight-tumor-lactate-as-a-druggable-node-in-cancer-immunity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: TUMOR LACTATE AS A DRUGGABLE NODE IN CANCER IMMUNITYBioCentury’s translational roundup also includes an RNA degrader as a broad-spectrum antiviralThu, 02 Jul 2026 06:12:55 -0700https://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopaminehttps://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopamine?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTPARKINSON’S PIPELINE PUSHES BEYOND DOPAMINECell therapies, α-synuclein programs and genetic targets are testing whether the field can finally bring disease modification closer to realityWed, 01 Jul 2026 16:19:20 -0700https://www.biocentury.com/article/660006/degette-s-primary-loss-a-blow-to-fda-reformshttps://www.biocentury.com/article/660006/degette-s-primary-loss-a-blow-to-fda-reforms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWDEGETTE’S PRIMARY LOSS A BLOW TO FDA REFORMSThe Colorado Democrat co-authored 21st Century Cures and built bipartisan consensus around fostering innovation and speeding drugs to patientsWed, 01 Jul 2026 15:33:30 -0700https://www.biocentury.com/article/659944/yellowstone-mining-hla-class-ii-for-tcr-therapieshttps://www.biocentury.com/article/659944/yellowstone-mining-hla-class-ii-for-tcr-therapies?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEYELLOWSTONE: MINING HLA CLASS II FOR TCR THERAPIESOxford spinout is using a 20-year AML biobank to develop TCR engagers against a largely untapped antigen classWed, 01 Jul 2026 13:02:40 -0700https://www.biocentury.com/article/659994/making-regulation-a-catalyst-not-a-barrier-for-u-k-life-sciences-lawrence-tallonhttps://www.biocentury.com/article/659994/making-regulation-a-catalyst-not-a-barrier-for-u-k-life-sciences-lawrence-tallon?utm_source=bc_rss&utm_medium=rssBIOCENTURY | GUEST COMMENTARYMAKING REGULATION A CATALYST, NOT A BARRIER, FOR U.K. LIFE SCIENCES — LAWRENCE TALLONMHRA CEO argues in a Guest Commentary that for the U.K.’s long-term health and prosperity, regulation should help lead, rather than follow, innovationWed, 01 Jul 2026 11:23:52 -0700https://www.biocentury.com/article/659987/thin-evidence-underpins-congress-probe-of-china-trial-consenthttps://www.biocentury.com/article/659987/thin-evidence-underpins-congress-probe-of-china-trial-consent?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWTHIN EVIDENCE UNDERPINS CONGRESS' PROBE OF CHINA TRIAL CONSENTHouse committee letters echo Capitol Hill memo, cite ethics concerns that are not unique to ChinaTue, 30 Jun 2026 16:05:07 -0700https://www.biocentury.com/article/659981/abivax-completes-round-trip-after-uc-malignancy-scarehttps://www.biocentury.com/article/659981/abivax-completes-round-trip-after-uc-malignancy-scare?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTABIVAX COMPLETES ROUND TRIP AFTER UC MALIGNANCY SCAREBioCentury’s Clinical Report June 24 – 30Tue, 30 Jun 2026 16:01:20 -0700https://www.biocentury.com/article/659925/fda-s-july-calendar-features-at-least-10-decision-dateshttps://www.biocentury.com/article/659925/fda-s-july-calendar-features-at-least-10-decision-dates?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTEFDA’S JULY CALENDAR FEATURES AT LEAST 10 DECISION DATESApplications include a cell therapy delayed from AprilTue, 30 Jun 2026 15:16:13 -0700https://www.biocentury.com/article/659982/wuxi-apptec-seeks-injunction-removing-chinese-military-designationhttps://www.biocentury.com/article/659982/wuxi-apptec-seeks-injunction-removing-chinese-military-designation?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWWUXI APPTEC SEEKS INJUNCTION REMOVING ‘CHINESE MILITARY’ DESIGNATIONMotion cites recent Anthropic win as precedent, reiterates lack of control by or affiliation with Chinese government, militaryTue, 30 Jun 2026 13:46:33 -0700https://www.biocentury.com/article/659971/chugai-brings-platform-first-partnering-to-south-san-franciscohttps://www.biocentury.com/article/659971/chugai-brings-platform-first-partnering-to-south-san-francisco?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSCHUGAI BRINGS PLATFORM-FIRST PARTNERING TO SOUTH SAN FRANCISCOJapanese pharma aims to turn U.S. academic visibility into early collaborations built around its antibody and macrocyclic peptide technologiesTue, 30 Jun 2026 13:28:52 -0700https://www.biocentury.com/article/659947/vc-backed-kartos-sells-to-ipsen-in-backloaded-agreement-deals-reporthttps://www.biocentury.com/article/659947/vc-backed-kartos-sells-to-ipsen-in-backloaded-agreement-deals-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSVC-BACKED KARTOS SELLS TO IPSEN IN BACKLOADED AGREEMENT: DEALS REPORTPlus: Novartis, Antares in discovery deal; Zymeworks buys Theravance; Germany-based Merck acquires tools company Bio-Techne; and moreMon, 29 Jun 2026 15:05:06 -0700https://www.biocentury.com/article/659952/mrgprx2-fails-key-csu-test-as-evommune-drops-urticaria-programhttps://www.biocentury.com/article/659952/mrgprx2-fails-key-csu-test-as-evommune-drops-urticaria-program?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTMRGPRX2 FAILS KEY CSU TEST AS EVOMMUNE DROPS URTICARIA PROGRAMPhase IIb miss with EVO756 clouds prospects for blocking a single mast-cell activation pathway in chronic hivesMon, 29 Jun 2026 14:51:53 -0700https://www.biocentury.com/article/659955/klomp-consolidates-power-at-hhs-oversees-fda-leadership-shufflehttps://www.biocentury.com/article/659955/klomp-consolidates-power-at-hhs-oversees-fda-leadership-shuffle?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWKLOMP CONSOLIDATES POWER AT HHS, OVERSEES FDA LEADERSHIP SHUFFLETrump has selected a pragmatic dealmaker to take charge of public health, signaling a shift from ideologyMon, 29 Jun 2026 14:42:19 -0700https://www.biocentury.com/article/659958/parkinson-s-deep-dive-fda-trial-reforms-a-biocentury-podcasthttps://www.biocentury.com/article/659958/parkinson-s-deep-dive-fda-trial-reforms-a-biocentury-podcast?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DISCOVERY & TRANSLATIONPARKINSON’S DEEP DIVE & FDA TRIAL REFORMS — A BIOCENTURY PODCASTPlus AZ’s obesity build-out and FDA’s reversion to the mean on regulatory decisionsMon, 29 Jun 2026 13:29:26 -0700https://www.biocentury.com/article/659801/building-out-in-obesityhttps://www.biocentury.com/article/659801/building-out-in-obesity?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTBUILDING OUT IN OBESITYAstraZeneca is building an obesity portfolio it hopes can compete beyond the GLP-1 incumbentsMon, 29 Jun 2026 12:35:37 -0700https://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceilinghttps://www.biocentury.com/article/659787/immunic-tests-nurr1-to-push-beyond-ms-s-inflammation-ceiling?utm_source=bc_rss&utm_medium=rssBIOCENTURY | PRODUCT DEVELOPMENTIMMUNIC TESTS NURR1 TO PUSH BEYOND MS’S INFLAMMATION CEILING Phase III candidate vidofludimus calcium will show whether pairing DHODH inhibition with direct neuroprotective effects can slow MS progressionFri, 26 Jun 2026 18:00:04 -0700https://www.biocentury.com/article/659932/house-committee-to-vote-on-china-investment-and-in-licensing-restrictionshttps://www.biocentury.com/article/659932/house-committee-to-vote-on-china-investment-and-in-licensing-restrictions?utm_source=bc_rss&utm_medium=rssBIOCENTURY | POLITICS, POLICY & LAWHOUSE COMMITTEE TO VOTE ON CHINA INVESTMENT AND IN-LICENSING RESTRICTIONSRules Committee will consider proposals to add BINSA, research restrictions, and domestic biomanufacturing support to the NDAAFri, 26 Jun 2026 16:21:18 -0700https://www.biocentury.com/article/659927/definium-s-805m-offering-leads-follow-on-quartet-public-equity-reporthttps://www.biocentury.com/article/659927/definium-s-805m-offering-leads-follow-on-quartet-public-equity-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCEDEFINIUM’S $805M OFFERING LEADS FOLLOW-ON QUARTET: PUBLIC EQUITY REPORTPlus: uniQure, MoonLake and Taysha round out group raising nearly $1.5B combinedFri, 26 Jun 2026 16:06:28 -0700https://www.biocentury.com/article/659929/chmp-joins-fda-in-challenging-tavneos-approval-basishttps://www.biocentury.com/article/659929/chmp-joins-fda-in-challenging-tavneos-approval-basis?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONCHMP JOINS FDA IN CHALLENGING TAVNEOS’ APPROVAL BASISRecommendation to revoke EU authorization follows FDA withdrawal proposal, with both agencies citing data integrity concernsFri, 26 Jun 2026 15:49:15 -0700https://www.biocentury.com/article/659934/upcoming-fda-adcomms-will-test-post-makary-independencehttps://www.biocentury.com/article/659934/upcoming-fda-adcomms-will-test-post-makary-independence?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONUPCOMING FDA ADCOMMS WILL TEST POST-MAKARY INDEPENDENCE Replimune and Capricor meetings revisit Prasad-era controversies, while peptide review will test MAHA’s influence over FDAFri, 26 Jun 2026 14:39:34 -0700https://www.biocentury.com/article/659905/rq-bio-raises-115m-to-advance-long-acting-antibody-prophylaxis-for-flu-venture-reporthttps://www.biocentury.com/article/659905/rq-bio-raises-115m-to-advance-long-acting-antibody-prophylaxis-for-flu-venture-report?utm_source=bc_rss&utm_medium=rssBIOCENTURY | FINANCERQ BIO RAISES $115M TO ADVANCE LONG-ACTING ANTIBODY PROPHYLAXIS FOR FLU: VENTURE REPORTPlus: Patient Square backs Osanni’s hub-and-spoke model; Nura moves ahead in neurodegeneration; and a handful of NewCos draw cashThu, 25 Jun 2026 14:41:40 -0700https://www.biocentury.com/article/659912/hengrui-rising-frank-jiang-on-building-a-global-biotechhttps://www.biocentury.com/article/659912/hengrui-rising-frank-jiang-on-building-a-global-biotech?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DEALSHENGRUI RISING: FRANK JIANG ON BUILDING A GLOBAL BIOTECHBehind the deals and R&D of China’s top biopharma Thu, 25 Jun 2026 12:54:14 -0700https://www.biocentury.com/article/659914/tryngolza-expansion-gives-ionis-its-first-prevalent-market-testhttps://www.biocentury.com/article/659914/tryngolza-expansion-gives-ionis-its-first-prevalent-market-test?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTRYNGOLZA EXPANSION GIVES IONIS ITS FIRST PREVALENT-MARKET TESTFDA approval moves Tryngolza from rare FCS into severe hypertriglyceridemia, giving Ionis its first shot at a broad cardiometabolic marketThu, 25 Jun 2026 12:35:58 -0700https://www.biocentury.com/article/659850/newco-boom-picks-up-pace-in-1h26https://www.biocentury.com/article/659850/newco-boom-picks-up-pace-in-1h26?utm_source=bc_rss&utm_medium=rssBIOCENTURY | DATA BYTENEWCO BOOM PICKS UP PACE IN 1H26Halfway through the year, at least 13 West-based companies have launched with Asian assets, nearly matching 2025’s full-year totalThu, 25 Jun 2026 08:54:40 -0700https://www.biocentury.com/article/659890/where-trialblazer-puts-fda-ahead-and-where-china-still-leadshttps://www.biocentury.com/article/659890/where-trialblazer-puts-fda-ahead-and-where-china-still-leads?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONWHERE TRIALBLAZER PUTS FDA AHEAD — AND WHERE CHINA STILL LEADSThe U.S. roadmap could speed trial starts, but China retains advantages in parallel review, faster IND pathways, and regulatory flexibilityWed, 24 Jun 2026 15:50:38 -0700https://www.biocentury.com/article/659888/tracking-fda-s-trialblazer-reformshttps://www.biocentury.com/article/659888/tracking-fda-s-trialblazer-reforms?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONTRACKING FDA’S TRIALBLAZER REFORMSSome actions are already complete, but the biggest changes to IND review, IRBs and trial enrollment remain aheadWed, 24 Jun 2026 15:25:03 -0700https://www.biocentury.com/article/659882/planned-reforms-could-narrow-but-not-close-u-s-china-trial-start-gaphttps://www.biocentury.com/article/659882/planned-reforms-could-narrow-but-not-close-u-s-china-trial-start-gap?utm_source=bc_rss&utm_medium=rssBIOCENTURY | REGULATIONPLANNED REFORMS COULD NARROW, BUT NOT CLOSE, U.S.-CHINA TRIAL START GAPOperation TrialBlazer combines short-term incremental reforms with attempts at transformational changeWed, 24 Jun 2026 15:10:06 -0700https://www.biocentury.com/article/659691/expedition-medicines-generative-covalent-chemistry-to-unlock-difficult-targets-at-scalehttps://www.biocentury.com/article/659691/expedition-medicines-generative-covalent-chemistry-to-unlock-difficult-targets-at-scale?utm_source=bc_rss&utm_medium=rssBIOCENTURY | EMERGING COMPANY PROFILEEXPEDITION MEDICINES: GENERATIVE COVALENT CHEMISTRY TO UNLOCK DIFFICULT TARGETS AT SCALEFlagship’s Expedition is training AI on proteome-wide reactivity data and quantum chemistry to design covalent small moleculesWed, 24 Jun 2026 14:47:26 -0700